Literature DB >> 9832285

Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18632 aerobic bacteria tested in 92 German centers.

H K Geiss1, G Beck.   

Abstract

The in vitro antibacterial activity of meropenem and up to 26 other antibiotics was compared under routine conditions at 92 German centers from March to June 1995 with use of the agar diffusion method against 18632 recent isolates from ICU--hemato-oncology--and pediatric patients. Overall, meropenem was the most active drug exhibiting a higher activity against gram-negative aerobes than imipenem, but somewhat less active against staphylococci and enterocooci. The overall resistance rates of most antibiotics tested was higher compared to the recently published surveillance data of the Paul-Ehrlich-Society in Germany. The main reason for this discrepancy is the higher percentage of test strains which were recovered from intensive care unit patients in the present study. These data confirm similar results from the USA and underscore the pressing need for the implementation of a nationwide antimicrobial surveillance system which is risk-stratified by hospital size, ICU- versus non-ICU-patients, and body site from which the isolates are recovered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832285     DOI: 10.1016/s0924-8579(98)00044-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I).

Authors:  Sung Wook Park; Jeoung Soon We; Gye Won Kim; Seong Hak Choi; Haeng Soon Park
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 3.  Meropenem: an updated review of its use in the management of intra-abdominal infections.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

4.  Two novel clinical presentations of Burkholderia cepacia infection.

Authors:  Chiranjoy Mukhopadhyay; Anudita Bhargava; Archana Ayyagari
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.